A Randomized, Open Label, Multi-center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir for the Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1)

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 29 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pritelivir (Primary) ; Cidofovir; Cidofovir; Foscarnet; Imiquimod; Imiquimod
Indications Herpes simplex virus infections
Focus Registrational; Therapeutic Use
Acronyms PRIOH-1
Sponsors AiCuris

Most Recent Events

01 Dec 2023 Imiquimod (Topical and IV solution) and Cidofovir topical and IV are added to the active comparators arm.
01 Dec 2023 Planned End Date changed from 1 Oct 2024 to 1 Apr 2025.
01 Dec 2023 Planned primary completion date changed from 1 Jun 2024 to 1 Jan 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight